GlassScriptPhysician profile
Martin M Keibel
NPI 1427067339
$2,221.82
in general payments reported to CMS, 2019-2025
25 companies · $81.84 in 2025
The $81.84 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,068 · 2020: $30.47 · 2023: $41.46 · 2025: $81.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $123.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $282.50 | 2019-2020 | |
| Pfizer INC. | $233.61 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $211.88 | 2019 | |
| Allergan, INC. | $204.94 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $188.26 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.61 | 2019 | |
| Astellas Pharma US INC | $101.75 | 2019 | |
| Exact Sciences Corporation | $97.03 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $88.05 | 2019 | |
| Glaxosmithkline, LLC. | $87.45 | 2019 | |
| Lilly USA, LLC | $85.14 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $83.40 | 2019 | |
| Merck Sharp & Dohme LLC | $60.88 | 2019 | |
| Scilex Pharmaceuticals INC. | $58.52 | 2019 | |
| Amgen INC. | $58.36 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $56.46 | 2019 | |
| Janssen Pharmaceuticals, INC | $42.29 | 2019 | |
| Shire North American Group INC | $39.24 | 2019 | |
| Abbvie INC. | $26.27 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $24.77 | 2019 | |
| Sanofi Pasteur INC. | $20.99 | 2019 | |
| Genentech USA, INC. | $20.83 | 2019 | |
| Eisai INC. | $20.27 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $13.22 | 2019 | |
| Seqirus USA INC | $13.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Keibel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.